Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced new preclinical data demonstrating the potential of AKTX-101, the Company's proprietary TROP2-targeted ADC utilizing its novel PH1 RNA spliceosome modulating payload, as a differentiated therapeutic approach for urothelial cancer in disease settings where currently available ADC therapies may have limited clinical benefit.

The findings demonstrated meaningful anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models including advanced urothelial cancer with limited response to currently approved ADC therapy, and tumors with acquired resistance following treatment with a first-generation TROP2-directed ADC. Collectively, the data provide additional validation for Akari's strategy of developing ADCs with a differentiated payload mechanism designed to address emerging limitations associated with existing ADC payload classes, such as microtubule and topoisomerase 1 inhibitors.